Food and Drug Administration Agency (FDA) approved drugs for AD treatment are either based on the inhibition of acetylcholinesterase (AChE), the enzyme that is part of the cholinergic system or on the inhibition of β-amyloid (Aβ) aggregation [2,3,4]. The gene discussed is ACHE; the disease is Alzheimer disease.